Caplyta and Tardive dyskinesia - a phase IV clinical study of FDA data

Summary:

Tardive dyskinesia is found among people who take Caplyta, especially for people who are male, 60+ old.

The phase IV clinical study analyzes which people take Caplyta and have Tardive dyskinesia. It is created by eHealthMe based on reports of 821 people who have side effects when taking Caplyta from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 07, 2023

821 people reported to have side effects when taking Caplyta.
Among them, 11 people (1.34%) have Tardive dyskinesia.

What is Caplyta?

Caplyta has active ingredients of lumateperone tosylate. eHealthMe is studying from 835 Caplyta users for its effectiveness, alternative drugs and more.

What is Tardive dyskinesia?

Tardive dyskinesia (a disorder that involves involuntary movements) is found to be associated with 1,969 drugs and 1,229 conditions by eHealthMe.

Number of Caplyta and Tardive dyskinesia reports submitted per year:

Gender of people who have Tardive dyskinesia when taking Caplyta *:

female: 36.36 %
male: 63.64 %

Age of people who have Tardive dyskinesia when taking Caplyta *:

Common drugs people take besides Caplyta *:

Common side effects people have besides Tardive dyskinesia *:

Headache (pain in head): 2 people, 18.18%
Withdrawal Syndrome (a discontinuation syndrome is a set of symptoms occurred due to discontinuation of substance): 1 person, 9.09%
Vision Blurred: 1 person, 9.09%
Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure): 1 person, 9.09%
Depression: 1 person, 9.09%
Drowsiness: 1 person, 9.09%
Dyskinesia (abnormality or impairment of voluntary movement): 1 person, 9.09%
Epinephrine Abnormal: 1 person, 9.09%
Fatigue (feeling of tiredness): 1 person, 9.09%
Hot Flush (sudden feelings of heat): 1 person, 9.09%

Common conditions people have *:

Bipolar Disorder (mood disorder): 3 people, 27.27%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 2 people, 18.18%
Bipolar Ii Disorder (characterized by at least one episode of hypomania and at least one episode of major depression): 2 people, 18.18%
Schizoaffective Disorder (a mental disorder characterized by disordered thought): 1 person, 9.09%
Psychotic Disorder: 1 person, 9.09%
Hypersensitivity: 1 person, 9.09%
Depression: 1 person, 9.09%
Asthma: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Caplyta and have Tardive dyskinesia?

Check whether Tardive dyskinesia is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Manjunatha N, Ganjekar S, Mahendra JV, Kilara N, Srinivasa R, "Tardive Dyskinesia Associated With Anastrozole", The Journal of neuropsychiatry and clinical neurosciences, 2013 Jan .

Related studies

How severe was Tardive dyskinesia and when was it recovered:

Tardive dyskinesia in Caplyta

Expand to all the drugs that have ingredients of lumateperone tosylate:

Tardive dyskinesia and drugs with ingredients of lumateperone tosylate

Alternative drugs to, pros and cons of Caplyta:

Caplyta (835 reports)

Tardive dyskinesia treatments and more:

Tardive dyskinesia (47,822 reports)

COVID vaccines that are related to Tardive dyskinesia:

Common drugs associated with Tardive dyskinesia:

Clopra: 17,562 reports
Metoclopramide: 17,562 reports
Reglan: 7,428 reports
Metoclopramide hydrochloride: 2,443 reports
Abilify: 2,311 reports
Risperdal: 1,668 reports
Seroquel: 1,665 reports
Ingrezza: 1,214 reports
Zyprexa: 793 reports
Risperidone: 790 reports

All the drugs that are associated with Tardive dyskinesia:

Tardive dyskinesia (1,969 drugs)

Common conditions associated with Tardive dyskinesia:

Indigestion: 3,363 reports
Bipolar disorder: 1,450 reports
Depression: 1,285 reports
Schizophrenia: 1,085 reports
Gastroesophageal reflux disease: 534 reports
Stress and anxiety: 485 reports

All the conditions that are associated with Tardive dyskinesia:

Tardive dyskinesia (1,229 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lumateperone tosylate (the active ingredients of Caplyta) and Caplyta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.